Oyster Point's OC-02 nasal spray meets in Phase IIb for dry eye

Oyster Point Pharma Inc. (Princeton, N.J.) said its OC-02 nasal spray met the primary endpoints in the double-blind, U.S. Phase IIb PEARL trial to treat dry eye disease. CEO Jeffrey Nau told BioCentury Oyster Point plans to begin a Phase III trial in 3Q19, with an NDA submission slated for 2020.

A potential first-in-class treatment, OC-02 is a nicotinic acetylcholine receptor (nAChR) agonist that stimulates the trigeminal nerve, accessible within the nose, to promote natural tear film production...